Protease inhibitor-induced nausea and vomiting is attenuated by a peripherally acting, opioid-receptor antagonist in a rat model

AIDS Research and Therapy

Volumn 6, Issue , 2009, Pages

  Yuan, Chun Su ^a,b   Wang, Chong Zhi ^a   Mehendale, Sangeeta R ^a   Aung, Han H ^a   Foo, Adela ^a   Israel, Robert J ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c A Subsidiary of Lantheus Holdings   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; KAOLIN; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PROTEINASE INHIBITOR; RITONAVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; FOOD INTAKE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 70049102536     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-6-19     Document Type: Article

References (30)

1. Sande M Volberding PA The Medical Management of AIDS Philadelphia: W.B. Saunders & Co 6 1999
2. Selgelid MJ Ethics and infectious disease Bioethics 2005, 19:272-289 10.1111/j.1467-8519.2005.00441.x 16167406
3. Proctor VE Tesfa A Tompkins DC Barriers to adherence to highly active antiretroviral therapy as expressed by people living with HIV/AIDS AIDS Patient Care STDS 1999, 13:535-544 10.1089/apc.1999.13.535 10813033
4. Barlett JG HIV: Current diagnosis, management, and treatment options PDR 2004
5. Carr A Improvement of the study, analysis, and reporting of adverse events associated with antiretroviral therapy Lancet 2002, 360:81-85 10.1016/S0140-6736(02)09341-8 12114062
6. Lichterfeld M Nischalke HD Bergmann F Wiesel W Rieke A Theisen A Fätkenheuer G Oette M Carls H Fenske S Nadler M Knechten H Wasmuth JC Rockstroh JK Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy HIV Med 2002, 3:37-43 10.1046/j.1464-2662.2001.00091.x 12059949
7. Gartland M AVANTI 3: A randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients Antivir Ther 2001, 6:127-134 11491417
8. Elperin A Sax P A patient's guide to protease inhibitors AIDS Clin Care 1996, 8:83-84 11363988
9. Ernest CS 2nd Hall SD Jones DR Mechanism-based inactivation of CYP3A by HIV protease inhibitors J Pharmacol Exp Ther 2005, 312:583-591 10.1124/ jpet.104.075416 15523003
10. Motwani B Khayr W Pharmacoenhancement of protease inhibitors Am J Ther 2006, 13:57-63 10.1097/00045391-200601000-00010 16428923
11. Mitchell D Wells C Hoch N Lind K Woods SC Mitchell LK Poison induced pica in rats Physiol Behav 1976, 17:691-697 10.1016/0031-9384(76)90171-2 1034944
12. Takeda N Hasegawa S Morita M Horii A Uno A Yamatodani A Matsunaga T Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats Methods Find Exp Clin Pharmacol 1995, 17:589-590 8786672
13. Takeda N Hasegawa S Morita M Matsunaga T Pica in rats is analogous to emesis: An animal model in emesis research Pharmacol Biochem Behav 1993, 45:817-821 10.1016/0091-3057(93)90126-E 8415820
14. Aung H Mehendale S Chang WT Wang CZ Xie JT Yuan CS Scutellaria baicalensis decreases ritonavir-induced nausea AIDS Res Ther 2005, 2:12 10.1186/1742-6405-2-12 1352373 16368007
15. Aung HH Dey L Mehendale S Xie JT Wu JA Yuan CS Scutellaria baicalensis extract decreases cisplatin-induced pica in rats Cancer Chemother Pharmacol 2003, 52:453-458 10.1007/s00280-003-0694-9 12942313
16. Aung HH Mehendale SR Xie JT Moss J Yuan CS Methylnaltrexone prevents morphine-induced kaolin intake in the rat Life Sci 2004, 74:2685-2691 10.1016/j.lfs.2003.08.047 15043984
17. Yuan CS Israel RJ Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects Expert Opin Investig Drugs 2006, 15:541-552 10.1517/13543784.15.5.541 16634692
18. Yuan CS Foss JF O'Connor M Osinski J Roizen MF Moss J Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine Drug Alcohol Depend 1998, 52:161-165 10.1016/ S0376-8716(98)00087-8 9800145
19. Meyer M Palliative care and AIDS: 2 - Gastrointestinal symptoms Int J STD AIDS 1999, 10:495-505 quiz 506-497 10.1258/0956462991914573 10471098
20. Padua CA Cesar CC Bonolo PF Acurcio FA Guimaraes MD High incidence of adverse reactions to initial antiretroviral therapy in Brazil Braz J Med Biol Res 2006, 39:495-505 16612473
21. Denissen JF Grabowski BA Johnson MK Buko AM Kempf DJ Thomas SB Surber BW Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans Drug Metab Dispos 1997, 25:489-501 9107549
22. Yamaji H Matsumura Y Yoshikawa Y Takada K Pharmacokinetic interactions between HIV-protease inhibitors in rats Biopharm Drug Dispos 1999, 20:241-247 10.1002/ (SICI)1099-081X(199907)20:5<241::AID-BDD182>3.0.CO;2-U 10594868
23. Shibata N Gao W Okamoto H Kishida T Iwasaki K Yoshikawa Y Takada K Drug interactions between HIV protease inhibitors based on physiologically-based pharmacokinetic model J Pharm Sci 2002, 91:680-689 10.1002/jps.10051 11920753
24. Kotake AN Kuwahara SK Burton E McCoy CE Goldberg LI Variations in demethylation of N-methylnaltrexone in mice, rats, dogs, and humans Xenobiotica 1989, 19:1247-1254 10.3109/00498258909043176 2618077
25. Osinski J Wang A Wu JA Foss JF Yuan CS Determination of methylnaltrexone in clinical samples by solid-phase extraction and high-performance liquid chromatography for a pharmacokinetics study J Chromatogr B Analyt Technol Biomed Life Sci 2002, 780:251-259 10.1016/S1570-0232(02)00527-5 12401350
26. Frich LM Borgbjerg FM Pain and pain treatment in AIDS patients: A longitudinal study J Pain Symptom Manage 2000, 19:339-347 10.1016/ S0885-3924(00)00140-8 10869874
27. Yuan CS Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects Ann Pharmacother 2007, 41:984-993 10.1345/aph.1K009 17504835
28. Gmerek DE Cowan A Woods JH Independent central and peripheral mediation of morphine-induced inhibition of gastrointestinal transit in rats J Pharmacol Exp Ther 1986, 236:8-13 3941402
29. Breitbart W Dibiase L Current perspectives on pain in AIDS Oncology 2002, 16:818-829 12088302
30. Sullivan MD Edlund MJ Fan MY Devries A Brennan Braden J Martin BC Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: The TROUP study Pain 2008, 138:245-246 10.1016/j.pain.2008.04.027 18583052